Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | GLS | O94925 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22012131 | 0.85 | CACNA1G (0.34) | HTR2CSLC6A4HTR2ACACNA1GCACNA1B | |
| SCHEMBL22012760 | 0.81 | HTR2C (0.34) | HTR2CSLC6A4HTR2ACACNA1GCACNA1B | |
| SCHEMBL22012128 | 0.80 | HTR2C (0.33) | HTR2CSLC6A4HTR2ACACNA1GCACNA1B | |
| SCHEMBL22012873 | 0.78 | HTR2C (0.33) | HTR2CSLC6A4HTR2ACACNA1GCACNA1B | |
| SCHEMBL22012130 | 0.77 | CACNA1G (0.32) | HTR2CSLC6A4HTR2ACACNA1GCACNA1B | |
| SCHEMBL20692086 | 0.75 | HTR2C (0.35) | HTR2CSLC6A4HTR2ACACNA1GCACNA1B | |
| SCHEMBL21810636 | 0.75 | HTR2C (0.35) | HTR2CSLC6A4CACNA1GCACNA1BCACNA1C | |
| SCHEMBL23569349 | 0.73 | — | — | |
| SCHEMBL21962701 | 0.72 | — | — | |
| SCHEMBL25033958 | 0.69 | HTR2C (0.31) | HTR2CSLC6A4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | HTR2C 3684/4885SLC6A4 2720/4885HTR2A 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.